# IN8bio Inc. (INAB)

Source: https://www.quantisnow.com/company/INAB
Generated: 2026-11-13T16:16:42.633Z

- Ticker: INAB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2021
- SEC CIK: 0001740279
- Website: in8bio.com

## About

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

## Latest INAB news and filings

- 2026-11-06 21:01 UTC [IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/in8bio-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-6778765)
- 2026-11-05 21:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by IN8bio Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-in8bio-inc-6776671)
- 2026-11-05 21:10 UTC [SEC Form 8-K] [IN8bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/in8bio-inc-filed-sec-form-8-k-results-of-operations-and-6776448)
- 2026-11-05 21:01 UTC [Earnings] [IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights](https://www.quantisnow.com/insight/in8bio-reports-third-quarter-2026-financial-results-and-recent-business-6775882)
- 2026-10-06 20:00 UTC [IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/in8bio-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-6738750)
- 2026-09-22 20:00 UTC [Conference Announcement] [IN8bio to Present at Sidoti Small-Cap Virtual Conference](https://www.quantisnow.com/insight/in8bio-to-present-at-sidoti-small-cap-virtual-conference-6722871)
- 2026-09-10 12:00 UTC [Conference Announcement] [IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/in8bio-to-present-at-hc-wainwright-28th-annual-global-investment-6710864)
- 2026-09-09 12:00 UTC [Leadership Update] [IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development](https://www.quantisnow.com/insight/in8bio-appoints-oxana-polyakova-phd-as-senior-vice-president-of-6709305)
- 2026-08-13 18:21 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by IN8bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-in8bio-inc-6679981)
- 2026-08-10 20:01 UTC [IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/in8bio-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-6673440)
- 2026-08-06 20:11 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by IN8bio Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-in8bio-inc-6669103)
- 2026-08-06 20:05 UTC [SEC Form 8-K] [IN8bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/in8bio-inc-filed-sec-form-8-k-results-of-operations-and-6668811)
- 2026-08-06 20:01 UTC [IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights](https://www.quantisnow.com/insight/in8bio-reports-second-quarter-2026-financial-results-and-recent-business-6668510)
- 2026-07-09 12:00 UTC [IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma](https://www.quantisnow.com/insight/in8bio-announces-publication-in-the-journal-of-clinical-oncology-demonstrating-6632398)
- 2026-06-03 12:30 UTC [IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies](https://www.quantisnow.com/insight/in8bio-announces-publication-in-nature-communications-highlighting-advances-in-gamma-delta-6586002)
- 2026-06-01 12:30 UTC [IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026](https://www.quantisnow.com/insight/in8bio-presents-updated-overall-survival-data-surpassing-195-months-for-6580787)
- 2026-06-01 10:56 UTC [SEC Form 8-K] [SEC Form 8-K filed by IN8bio Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-in8bio-inc-6580489)
- 2026-06-01 10:17 UTC [SEC Form 424B5] [SEC Form 424B5 filed by IN8bio Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-in8bio-inc-6580423)
- 2026-05-29 21:41 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by IN8bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-in8bio-inc-6580022)
- 2026-05-29 21:39 UTC [SEC Form 4] [Director Fairbairn Emily gifted 724,637 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-fairbairn-emily-gifted-724637-shares-sec-form-4-6580020)
- 2026-05-20 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by IN8bio Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-in8bio-inc-6564142)
- 2026-05-18 21:14 UTC [SEC Form S-3] [Amendment: SEC Form S-3/A filed by IN8bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-3a-filed-by-in8bio-inc-6560933)
- 2026-05-14 12:00 UTC [IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma](https://www.quantisnow.com/insight/in8bio-presents-new-translational-data-demonstrating-deltex-dri-reshapes-the-6552451)
- 2026-05-12 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Epperly Corinne](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-epperly-corinne-6548478)
- 2026-05-12 20:30 UTC [SEC Form 4] [SEC Form 4 filed by CEO Ho William Tai-Wei](https://www.quantisnow.com/insight/sec-form-4-filed-by-ceo-ho-william-tai-wei-6548473)
- 2026-05-12 20:30 UTC [SEC Form 4] [SEC Form 4 filed by EVP and CSO Lamb Lawrence](https://www.quantisnow.com/insight/sec-form-4-filed-by-evp-and-cso-lamb-lawrence-6548470)
- 2026-05-12 20:30 UTC [SEC Form 4] [SEC Form 4 filed by President and COO Rochlin Kate](https://www.quantisnow.com/insight/sec-form-4-filed-by-president-and-coo-rochlin-kate-6548469)
- 2026-05-12 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Fairbairn Emily](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-fairbairn-emily-6548468)
- 2026-05-12 20:30 UTC [SEC Form 4] [SEC Form 4 filed by CHIEF FINANCIAL OFFICER Mccall Patrick](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-mccall-patrick-6548467)
- 2026-05-12 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Greenwood Luba](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-greenwood-luba-6548465)
- 2026-05-12 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Brandt Peter C.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-brandt-peter-c-6548461)
- 2026-05-12 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Graff Jeremy R.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-graff-jeremy-r-6548453)
- 2026-05-07 21:22 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by IN8bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-in8bio-inc-6540321)
- 2026-05-07 21:21 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by IN8bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-in8bio-inc-6540313)
- 2026-05-07 21:21 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by IN8bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-in8bio-inc-6540308)
- 2026-05-07 21:20 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by IN8bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-in8bio-inc-6540306)
- 2026-05-07 21:19 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by IN8bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-in8bio-inc-6540300)
- 2026-05-07 21:18 UTC [SEC Form S-8] [SEC Form S-8 filed by IN8bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-in8bio-inc-6540292)
- 2026-05-07 20:32 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by IN8bio Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-in8bio-inc-6539858)
- 2026-05-07 20:31 UTC [SEC Form 8-K] [IN8bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/in8bio-inc-filed-sec-form-8-k-results-of-operations-and-6539817)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/INAB
- Earnings history: https://www.quantisnow.com/earnings/INAB
- Dividend history: https://www.quantisnow.com/dividends/INAB
- Insider transactions: https://www.quantisnow.com/insiders/INAB
- Options chain: https://www.quantisnow.com/options/INAB
- SEC 8-K filings only: https://www.quantisnow.com/company/INAB/8-k
- RSS and alerts for INAB: https://www.quantisnow.com/docs/rss-feeds.md